Impact of TMB, PD-L1 , genomic features, and pneumonitis on CRT and durvalumab response in stage III NSCLC - João Alessi

Impact of TMB, PD-L1 , genomic features, and pneumonitis on CRT and durvalumab response in stage III NSCLC – João Alessi

Glad to share our paper recently published in Nature. In which, we report the impact of TMB, PD-L1 , genomic features, and pneumonitis on CRT and durvalumab response in stage III NSCLC. Collaboration b/w Dana-Farber and Memorial Sloan Kettering Radiation Oncology.

For article: Click here

Source: João Alessi/Twitter

cancer Dana-Farber Durvalumab João Alessi Memorial Sloan Kettering Radiation Oncology OncoDaily Oncology pneumonitis